PORTLAND, Ore., Aug. 11, 2016 /PRNewswire/ -- Semler
Scientific, Inc. (OTCQB: SMLR; "Semler"), an emerging growth
company that provides technology solutions to improve the clinical
effectiveness and efficiency of healthcare insurers and physician
groups, announced today that its common stock will be delisted from
the NASDAQ Capital Market and that suspension of trading in the
shares was effective at the open of business on August 11, 2016 for failure to regain compliance
with the required $2,500,000 minimum
stockholders' equity for continued listing within the compliance
periods afforded by the NASDAQ's hearings panel.
Semler expects to begin trading on the OTCQB® on
August 11, 2016 under the symbol
SMLR. Investors can find current financial disclosure and
Real-Time Level 2 quotes for Semler's stock on
www.otcmarkets.com.
NASDAQ informed Semler that it would complete the delisting by
filing a Form 25 Notification of Delisting with the Securities and
Exchange Commission, after applicable appeals periods have
lapsed. The delisting becomes effective ten days after the
Form 25 is filed.
About Semler Scientific, Inc.:
Semler Scientific, Inc., is an emerging growth company that
provides technology solutions to improve the clinical effectiveness
and efficiency of healthcare insurers and physician groups.
Our mission is to develop, manufacture and market innovative
proprietary products and services that assist our customers in
evaluating and treating chronic diseases. Our first patented and
U.S. Food and Drug Administration, or FDA, cleared product,
introduced commercially in 2011, measured arterial blood flow in
the extremities to aid in the diagnosis of peripheral arterial
disease. In March 2015 we received
FDA 510(k) clearance for the next generation version of this
product named QuantaFlo™, which was commercially launched in
August 2015. In April 2015, we launched our multi-test service
platform, WellChec™, to more comprehensively evaluate our
customers' patients for chronic disease, including heart attacks
and strokes. We believe the combination of our proprietary test,
QuantaFlo™, and our multi-test service platform, WellChec™,
position us to provide valuable information to our insurance
company and physician customers, which in turn permit them to
better guide patient care. Additional information about Semler can
be found at semlerscientific.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/semler-scientific-inc-to-begin-trading-on-otcqb-300312678.html
SOURCE Semler Scientific, Inc.